Phase II study of topotecan and bevacizumab in advanced, refractory non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 5, 2013, Pages 495-501

  Powell, Steven F ^a   Beitinjaneh, Amer ^a   Tessema, Mathewos ^b   Bliss, Robin L ^a   Kratzke, Robert A ^a   Leach, Joseph ^c   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c Park Nicollet Research Institute   (United States)

Author keywords

Bevacizumab; ISG15 expression; Non small cell lung cancer; Refractory; Second line therapy; Topotecan

Indexed keywords

BEVACIZUMAB; CREATININE; TOPOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CAVA VEIN DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONTINUOUS INFUSION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFECTION; INTERFERON STIMULATED GENE 15; INTESTINE OBSTRUCTION; LOSS OF APPETITE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PSEUDOGOUT; SIDE EFFECT; SUPERIOR CAVA VEIN THROMBOSIS; SUPERIOR VENA CAVA THROMBOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; VISUAL IMPAIRMENT;

BEVACIZUMAB; ISG15 EXPRESSION; NON-SMALL-CELL LUNG CANCER; REFRACTORY; SECOND-LINE THERAPY; TOPOTECAN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TOPOTECAN;

EID: 84883758283     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.04.009     Document Type: Article

References (22)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. F.V. Fossella, R. DeVore, and R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2000 2354 2362
3. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
4. F.A. Shepherd, J.R. Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 252 2005 123 132
5. C.G. Azzoli, S. Baker, and S. Temin American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer J Clin Oncol 27 2009 6251 6266
6. N. Ferrara The role of vascular endothelial growth factor in pathological angiogenesis Breast Cancer Res Treat 36 1995 127 137
7. G. Fontanini, M. Lucchi, and S. Vignati Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study J Natl Cancer Inst 89 1997 881 886
8. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
9. J. Cassidy, S. Clarke, and E. Díaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
10. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New Engl J Med 355 2006 2542 2550
11. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
12. R.S. Herbst, V.J. O'Neill, and L. Fehrenbacher Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 2007 4743 4750
13. R. Ramlau, R. Gervais, and M. Krzakowski Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer J Clin Oncol 24 2006 2800 2807
14. T. Lynch, L. Kalish, and G. Strasuss Phase II study of topotecan in metastatic non-small-cell lung cancer J Clin Oncol 12 1994 347 352
15. T. Levy, M. Inbar, and J. Menczer Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer Gynecol Oncol 95 2004 686 690
16. S.D. Desai, L.M. Wood, and Y.C. Tsai ISG15 as a novel tumor biomarker for drug sensitivity Mol Cancer Ther 7 2008 1430 1439
17. M. Tessema, C.M. Yingling, and C.L. Thomas SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15 Oncogene 31 2012 4107 4116
18. M. Tessema, R. Willink, and K. Do Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25 Cancer Res 68 2008 1707 1714
19. T.D. Schmittgen, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nat Protoc 3 2008 1101 1108
20. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026
21. V. Ranpura, S. Hapani, and S. Wu Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis JAMA 305 2011 487 494
22. K.F. McGonigle, H.G. Muntz, and J. Vuky Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study Cancer 117 2011 3731 3740